Form 4: Mirum Pharmaceuticals Executive Peter Radovich Reports Stock Transactions
SEC Form 4 Filing
Peter Radovich, President and COO of Mirum Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- Peter Radovich, the President and COO of Mirum Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On January 23, 2025, Radovich acquired 5,750 shares of common stock through the vesting of restricted stock units.
- On January 24, 2025, Radovich sold 3,177 shares of common stock at a price of $47.9245 per share.
- Following these transactions, Radovich directly owns 29,588 shares of common stock.
- Radovich also owns 11,500 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be informative for investors.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of company leadership.
Key Dates
| Date | Description |
|---|---|
| 01/23/2024 | Vesting Commencement Date for restricted stock units |
| 01/23/2025 | Acquisition of 5,750 shares of common stock through vesting of restricted stock units |
| 01/24/2025 | Sale of 3,177 shares of common stock at $47.9245 per share |
| 01/27/2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.